Abstract
The efficacy of two mesoionic derivatives (MI-H-H and MI-4-OCH(3)) was evaluated in CBA/J mice infected with Leishmania amazonensis. Treatment with these compounds demonstrated that the MI-4-OCH(3) derivative and the reference drug meglumine antimoniate (Glucantime) presented significant activity relative to an untreated control. No apparent hepatic or renal toxicity due to these mesoionic compounds was found.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antiprotozoal Agents / therapeutic use*
-
Antiprotozoal Agents / toxicity
-
Blood Cell Count
-
Leishmania mexicana*
-
Leishmaniasis, Cutaneous / blood
-
Leishmaniasis, Cutaneous / drug therapy*
-
Leishmaniasis, Cutaneous / psychology
-
Lymph Nodes / parasitology
-
Meglumine / adverse effects
-
Meglumine / therapeutic use
-
Meglumine Antimoniate
-
Mice
-
Mice, Inbred CBA
-
Nitric Oxide / metabolism
-
Organometallic Compounds / adverse effects
-
Organometallic Compounds / therapeutic use
-
Structure-Activity Relationship
-
Thiadiazoles / therapeutic use*
-
Thiadiazoles / toxicity
Substances
-
1,3,4-thiadiazolium-2-aminide
-
Antiprotozoal Agents
-
Organometallic Compounds
-
Thiadiazoles
-
Nitric Oxide
-
Meglumine
-
Meglumine Antimoniate